Oncotarget

Research Papers:

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy

Daniel O’Neill _, Dominic Jones, Mark Wade, James Grey, Sirintra Nakjang, Wenrui Guo, David Cork, Barry R. Davies, Steve R. Wedge, Craig N. Robson, Luke Gaughan

PDF |  HTML  |  Supplementary Files  |  Author Information  |  Order a Reprint

Oncotarget. 2015; 6:26029-26040. https://doi.org/10.18632/oncotarget.4347

Metrics: PDF 582 views  |   HTML 285 views  |   ?  


Abstract

Daniel O’Neill2, Dominic Jones1, Mark Wade1, James Grey1, Sirintra Nakjang1, Wenrui Guo1, David Cork1, Barry R. Davies2, Steve R. Wedge1, Craig N. Robson1, Luke Gaughan1

1Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK

2AstraZeneca, Innovative Medicines, Discovery Sciences, Cambridge Science Park, Cambridge, CB4 0WG, UK

Correspondence to:

Luke Gaughan, e-mail: luke.gaughan@ncl.ac.uk

Keywords: prostate cancer, androgen receptor, mutation, anti-androgen-resistance, SGK1

Received: March 04, 2015     Accepted: July 08, 2015     Published: July 20, 2015

ABSTRACT

The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection of AR mutations that convert anti-androgens to agonists enabling the retention of androgenic signalling in CRPC. To improve our understanding of these receptors in advanced disease we developed a physiologically-relevant model to analyse the global functionality of AR mutants in CRPC. Using the bicalutamide-activated ARW741L/C mutation as proof of concept, we demonstrate that this mutant confers an androgenic-like signalling programme and growth promoting phenotype in the presence of bicalutamide. Transcriptomic profiling of ARW741L highlighted key genes markedly up-regulated by the mutant receptor, including TIPARP, RASD1 and SGK1. Importantly, SGK1 expression was found to be highly expressed in the KUCaP xenograft model and a CRPC patient biopsy sample both of which express the bicalutamide-activated receptor mutant. Using an SGK1 inhibitor, ARW741L transcriptional and growth promoting activity was reduced indicating that exploiting functional distinctions between receptor isoforms in our model may provide new and effective therapies for CRPC patients.

Author Information

Daniel O’Neill
Primary Contact  _

Dominic Jones

Mark Wade

James Grey

Sirintra Nakjang

Wenrui Guo

David Cork

Barry R. Davies

Steve R. Wedge

Craig N. Robson

Luke Gaughan


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4347